Research
Hormonal
Gamma-linolenic acid (GLA) exhibits tumoricidal activity against various cancers (breast, pancreas, colon, brain) and inhibits metastasis by downregulating osteonectin and stimulating metastasis suppressor genes.
GLA shows promise in laboratory and some clinical settings for fighting cancer cells and preventing spread, particularly when combined with standard treatments. It may help reduce side effects of chemotherapy and improve drug efficacy. Consult your oncologist before use.
ModerateSupportsMEDIUM confidence
GLA has been shown to exert tumoricidal activity against a variety of cancers including cancers of breast, pancreas, colon, brain, etc. [17,21,22,37,38]. GLA also inhibits metastasis of cancer cells [22,39-41].
Why this rating
Based on in-vitro studies and some clinical trials, but the paper is a review.
Source
Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Rakesh Kapoor et al. · Current Pharmaceutical Biotechnology · 2006
DOI 10.2174/138920106779116874
narrative_reviewCited 354×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gamma-linolenic acid (GLA) supplementation reduces inflammation and joint symptoms in rheumatoid arthritis patients, acting as an NSAID-sparing agent by producing anti-inflammatory prostaglandins (PGE1) and leukotrienes (LTB4 inhibition).Moderate
- Gamma-linolenic acid (GLA) improves the efficacy and reduces the side effects of tamoxifen in breast cancer patients, including improving transcutaneous absorption.Moderate
- Gamma-linolenic acid (GLA) improves nerve conduction velocity in diabetic patients, leading to improved blood flow and reduced tingling in extremities.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →